Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.
作者信息
Robinson Philip C, Richards Duncan, Tanner Helen L, Feldmann Marc
机构信息
Faculty of Medicine, University of Queensland, Brisbane, QLD, Australia.
Metro North Hospital and Health Service, Brisbane, QLD, Australia.
出版信息
Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.
Abstract
摘要
相似文献
1
Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.
Lancet Rheumatol. 2020 Nov;2(11):e653-e655. doi: 10.1016/S2665-9913(20)30309-X. Epub 2020 Sep 5.
2
Why Rehabilitation must have priority during and after the COVID-19-pandemic: A position statement of the Global Rehabilitation Alliance.
J Rehabil Med. 2020 Jul 30;52(7):jrm00081. doi: 10.2340/16501977-2713.
3
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.
Clin Trials. 2020 Oct;17(5):491-500. doi: 10.1177/1740774520943846. Epub 2020 Aug 20.
4
Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.
Gastroenterology. 2014 Sep;147(3):618-627.e3. doi: 10.1053/j.gastro.2014.05.008. Epub 2014 May 21.
5
It is unprecedented: trial management during the COVID-19 pandemic and beyond.
Trials. 2020 Sep 11;21(1):784. doi: 10.1186/s13063-020-04711-6.
6
Vitamin D Supplementation to Prevent COVID-19 Infections and Deaths-Accumulating Evidence from Epidemiological and Intervention Studies Calls for Immediate Action.
Nutrients. 2021 Jan 28;13(2):411. doi: 10.3390/nu13020411.
7
Optimizing anti-TNF treatments in inflammatory bowel disease.
Autoimmun Rev. 2014 Jan;13(1):24-30. doi: 10.1016/j.autrev.2013.06.002. Epub 2013 Jun 19.
8
The COVID-19 response must integrate people living with HIV needs in Sub-Saharan Africa: the case of Mali.
Trop Med Health. 2020 Jun 3;48:41. doi: 10.1186/s41182-020-00228-5. eCollection 2020.
9
Systematic assessment of factors influencing preferences of Crohn's disease patients in selecting an anti-tumor necrosis factor agent (CHOOSE TNF TRIAL).
Inflamm Bowel Dis. 2012 Aug;18(8):1523-30. doi: 10.1002/ibd.21888. Epub 2011 Oct 10.
10
Molecular mechanisms of action of anti-TNF-α agents - Comparison among therapeutic TNF-α antagonists.
Cytokine. 2018 Jan;101:56-63. doi: 10.1016/j.cyto.2016.08.014. Epub 2016 Aug 24.
引用本文的文献
1
Secondary metabolites of Alternaria alternate appraisal of their SARS-CoV-2 inhibitory and anti-inflammatory potentials.
PLoS One. 2025 Jan 24;20(1):e0313616. doi: 10.1371/journal.pone.0313616. eCollection 2025.
2
The Impact of Infliximab on Hyperinflammation State in Hospitalized COVID-19 Patients: A Retrospective Study.
Medicina (Kaunas). 2024 Oct 11;60(10):1670. doi: 10.3390/medicina60101670.
3
Network-based integrative multi-omics approach reveals biosignatures specific to COVID-19 disease phases.
Front Mol Biosci. 2024 Jul 8;11:1393240. doi: 10.3389/fmolb.2024.1393240. eCollection 2024.
4
analysis of the impact of toxic metals on COVID-19 complications: molecular insights.
Arh Hig Rada Toksikol. 2024 Jun 29;75(2):102-109. doi: 10.2478/aiht-2024-75-3819. eCollection 2024 Jun 1.
5
A phosphodiesterase-4 inhibitor reduces lung inflammation and fibrosis in a hamster model of SARS-CoV-2 infection.
Front Immunol. 2023 Oct 2;14:1270414. doi: 10.3389/fimmu.2023.1270414. eCollection 2023.
6
SARS-CoV-2 mouse adaptation selects virulence mutations that cause TNF-driven age-dependent severe disease with human correlates.
Proc Natl Acad Sci U S A. 2023 Aug 8;120(32):e2301689120. doi: 10.1073/pnas.2301689120. Epub 2023 Jul 31.
7
Prevalence and complication of COVID-19 in patients with ankylosing spondylitis (AS) and its relationship with TNF-a inhibitors.
Immun Inflamm Dis. 2023 Jun;11(6):e915. doi: 10.1002/iid3.915.
8
Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome.
Sci Rep. 2023 Apr 20;13(1):6456. doi: 10.1038/s41598-023-33484-6.
9
Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries.
Ann Rheum Dis. 2023 May;82(5):698-709. doi: 10.1136/ard-2022-223499. Epub 2023 Feb 14.
10
Carotenoids as potential inhibitors of TNFα in COVID-19 treatment.
PLoS One. 2022 Dec 27;17(12):e0276538. doi: 10.1371/journal.pone.0276538. eCollection 2022.
本文引用的文献
1
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Nat Med. 2020 Oct;26(10):1636-1643. doi: 10.1038/s41591-020-1051-9. Epub 2020 Aug 24.
2
SARS CoV-2 infection among patients using immunomodulatory therapies.
Ann Rheum Dis. 2021 Feb;80(2):269-271. doi: 10.1136/annrheumdis-2020-218580. Epub 2020 Aug 5.
3
Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure-a cautionary case series.
Crit Care. 2020 Jul 17;24(1):444. doi: 10.1186/s13054-020-03158-0.
4
Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.
Sci Immunol. 2020 Jul 10;5(49). doi: 10.1126/sciimmunol.abd1554.
5
Infliximab for severe ulcerative colitis and subsequent SARS-CoV-2 pneumonia: a stone for two birds.
Gut. 2021 Mar;70(3):623-624. doi: 10.1136/gutjnl-2020-321760. Epub 2020 Jun 17.
6
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.
Ann Rheum Dis. 2020 Jul;79(7):859-866. doi: 10.1136/annrheumdis-2020-217871. Epub 2020 May 29.
7
Pediatric Crohn Disease and Multisystem Inflammatory Syndrome in Children (MIS-C) and COVID-19 Treated With Infliximab.
J Pediatr Gastroenterol Nutr. 2020 Aug;71(2):153-155. doi: 10.1097/MPG.0000000000002809.
8
Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry.
Gastroenterology. 2020 Aug;159(2):481-491.e3. doi: 10.1053/j.gastro.2020.05.032. Epub 2020 May 18.
9
Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.
Lancet. 2020 May 2;395(10234):1407-1409. doi: 10.1016/S0140-6736(20)30858-8. Epub 2020 Apr 9.
10
Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
J Autoimmun. 2008 Sep;31(2):175-9. doi: 10.1016/j.jaut.2008.07.002. Epub 2008 Aug 15.
Zotero 插件